Clinical trial
A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer�s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106
To evaluate the safety and tolerability of repeated subcutaneous (s.c.) injections of 150?g CAD106 in patients with mild AD over the 52 weeks of the study.
| Category | Value |
|---|---|
| Study start date | 2007-09-12 |